Accessible Cancer Care
Faced with shortages of inexpensive essential medicines and increasing prices of innovative, potentially curative therapies reaching the clinic, we need to rethink the allocation of finite resources to secure the best possible care for all cancer patients while reducing the number of people who develop the disease in the future. By offering independent decision-making tools like the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) to support sustainability in oncology, developing locally adapted, value-based models of medicine reimbursement and targeting health inequalities in high and low-income settings alike, we can ensure that optimal care becomes accessible to everyone, everywhere.